We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $580M
1-Year Est. Return 29.81%
This Fund
S&P 500
This Quarter Est. Return
-9.07%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$155M
AUM Growth
-$12.2M
Cap. Flow
+$10.8M
Cap. Flow %
6.97%
Top 10 Hldgs %
72.2%
Holding
43
New
7
Increased
12
Reduced
13
Closed
11

Top Buys

Rank Stock Value
1
MGTX icon
MeiraGTx Holdings
MGTX
+$5.86M
2
CRL icon
Charles River Laboratories
CRL
+$4.94M
3
CUE icon
Cue Biopharma
CUE
+$4.82M
4
PRTA icon
Prothena Corp
PRTA
+$4.53M
5
STTK icon
Shattuck Labs
STTK
+$3.05M

Top Sells

Rank Stock Value
1
ZGNX
Zogenix, Inc.
ZGNX
+$5.9M
2
EHC icon
Encompass Health
EHC
+$5.4M
3
OSCR icon
Oscar Health
OSCR
+$5.12M
4
ARNA
Arena Pharmaceuticals Inc
ARNA
+$4.18M
5
MORF
Morphic Holding, Inc. Common Stock
MORF
+$3.45M

Sector Composition

Rank Sector Weight
1 Healthcare 90.33%
2 Miscellaneous 8.26%
3 Industrials 1.41%
4 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NEO icon
26
NeoGenomics
NEO
$2.32B
$772K 0.5%
+63,524
New +$1.34M
OGN icon
27
PUT
Organon & Co
OGN
$3.61B
$699K 0.45%
+20,000
New +$684K
CGTX icon
28
Cognition Therapeutics
CGTX
$97M
$660K 0.43%
240,080
-61,899
-20% -$239K
PRQR icon
29
ProQR Therapeutics
PRQR
$323M
$542K 0.35%
599,288
+242,671
+68% +$813K
SIOX
30
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$449K 0.29%
670,300
-131,880
-16% -$112K
IOVA icon
31
Iovance Biotherapeutics
IOVA
$3.63B
$333K 0.22%
20,000
-48,800
-71% -$755K
CBAY
32
DELISTED
Cymabay Therapeutics
CBAY
$292K 0.19%
93,923
-72,852
-44% -$229K
MRNA icon
33
Moderna
MRNA
$55.1B
– –
-3,700
Closed -$940K
PGNY icon
34
PUT
Progyny
PGNY
$1.99B
– –
-50,000
Closed -$2.52M
PRCT icon
35
Procept Biorobotics
PRCT
$1.19B
– –
-20,000
Closed -$500K
PRTA icon
36
CALL
Prothena Corp
PRTA
$479M
– –
-52,100
Closed -$2.57M
WST icon
37
PUT
West Pharmaceutical
WST
$23.7B
– –
-1,500
Closed -$704K
XCUR icon
38
Exicure
XCUR
$8.44M
– –
-16,177
Closed -$490K
MORF
39
DELISTED
Morphic Holding, Inc. Common Stock
MORF
– –
-72,898
Closed -$3.45M
PANA
40
DELISTED
Panacea Acquisition Corp. II Class A Ordinary Shares
PANA
– –
-195,855
Closed -$1.9M
ARNA
41
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-45,000
Closed -$4.18M
ODT
42
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
– –
-298,900
Closed -$404K
ZGNX
43
DELISTED
Zogenix, Inc.
ZGNX
– –
-362,909
Closed -$5.9M
1
2

Similar funds

SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
CCWM
Correct Capital Wealth Management Clayton, Missouri $580M AUM 16.45% 1-Year Est. Return
CMA
Cedar Mountain Advisors Lake Oswego, Oregon $581M AUM 18.16% 1-Year Est. Return
RIS
Retirement Income Solutions Ann Arbor, Michigan $581M AUM 19.42% 1-Year Est. Return
MFS
McNamara Financial Services Marshfield, Massachusetts $580M AUM 17.89% 1-Year Est. Return
GFI
Global Frontier Investments Charleston, South Carolina $581M AUM 8.55% 1-Year Est. Return
PWM
Praetorian Wealth Management Carmel, California $580M AUM 19.43% 1-Year Est. Return
CA
COFG Advisors Oak Brook, Illinois $579M AUM

Prosight Management's Q1 2022 Portfolio in Review

As of Q1 2022, Prosight Management held 43 positions worth $155M, down 7.3% from $167M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Prosight Management deployed $10.8M of net new capital in Q1 2022, opening 7 new positions and adding to 12 existing holdings. Its largest new stake was MeiraGTx Holdings: 380,700 shares worth $5.27M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 88% a quarter earlier, followed by Miscellaneous and Industrials.

On the sell side, the largest reduction was Encompass Health, an estimated $5.4M trimmed.

  • Prosight Management's largest Q1 2022 buy was MeiraGTx Holdings: 380,700 shares worth $5.27M.
  • Prosight Management added most to Charles River Laboratories in Q1 2022, an estimated $4.94M increase.
  • Prosight Management's biggest Q1 2022 reduction was Encompass Health, cutting an estimated $5.4M.
  • Prosight Management fully exited Zogenix, Inc. in Q1 2022, selling an estimated $5.9M.
  • Prosight Management's ten largest holdings make up 72% of its $155M portfolio in Q1 2022.
  • Prosight Management opened 7 new positions and closed 11 in Q1 2022.
  • Prosight Management's portfolio value fell 7.3% quarter-over-quarter to $155M.

Based on Prosight Management's 13F filing for Q1 2022, filed 16 May 2022.